// App-Quantinova.ai

: Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study

Researchers

Presenter

  • Craig I. Coleman

Principal Investigators

  • Alexander G. Turpie

  • Thomas J. Bunz

  • Jan Beyer-Westendorf

  • William L Baker

Medical Centers

  • School of Pharmacy, University of Connecticut School of Pharmacy, Suffield, CT

  • Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, ON, Canada

  • New England Health Analytics, LLC, Granby, CT

  • King's Thrombosis Service, Department of Haematology, King's College London, Dresden, Germany

  • School of Pharmacy, University of Connecticut, Storrs, CT

Locations

  • United States

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Central Nervous System (CNS)

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Inflammatory bowel disease

  • Venous thrombosis

  • Chronic kidney disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Renal disease

  • Congestive heart failure

  • Solid malignancies

  • Trauma

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved